The Sant Pau Research Institute (IR Sant Pau) has approved the creation of the new research group Gynecological and Breast Pathologies, focused on studying the main gynecological and breast diseases, both benign and malignant. The group is coordinated by Dr. Silvia Cabrera, a specialist in gynecologic oncology, who will lead this new unit with the aim of integrating care, teaching, and research through a multidisciplinary and translational approach.

Dr. Cabrera holds a degree in medicine and surgery from the University of Barcelona and is a specialist in gynecology and obstetrics. She has developed her professional and research career in the field of gynecologic oncology and gynecologic surgery, with a prominent focus on the prevention, diagnosis, and treatment of gynecologic and breast cancer. She is currently Clinical Head of Gynecology at Hospital de Sant Pau and has extensive research and teaching experience, reinforcing the leadership of this new group.

Research Oriented Toward Patients’ Needs

Gynecological and breast pathologies have a major impact on women’s health. The incidence of certain gynecologic and breast cancers is expected to increase, linked to growing exposure to environmental risk factors. At the same time, there is an increasing need to address diseases that have long been overlooked, such as uterine fibroids, endometriosis, and infertility, which significantly affect patients’ quality of life. In this context, the new group aims to generate specific knowledge and promote research lines that help better understand these pathologies and improve strategies for prevention, diagnosis, and treatment.

The group’s research is structured into three main lines. The first focuses on gynecologic and breast neoplasms, with particular attention to cancers of the endometrium, ovary, cervix, vulva, and vagina, as well as breast cancer and precancerous lesions that may progress to malignancy. The second line addresses benign pathologies with a high impact on women’s quality of life, such as endometriosis, uterine fibroids, chronic pelvic pain, or genital prolapse, which, although not life-threatening, can severely impact physical, reproductive, and emotional well-being. Finally, the third research line focuses on gynecologic and reproductive endocrinology, with special interest in hormonal disorders related to fertility, the menstrual cycle, and ovarian function.

“The creation of this group represents a step forward in raising awareness of and responding to diseases that directly affect women’s lives, both in the oncologic field and in the context of benign pathologies,” says Dr. Cabrera.

A Consolidated and Multidisciplinary Team

The research will take place in a high-complexity hospital environment, where knowledge generation is inseparable from clinical care and teaching. The commitment to a multidisciplinary and translational approach will ensure that scientific advances are rapidly transferred to clinical practice. The goal is to improve the prognosis of patients with malignant diseases and the quality of life of those living with benign conditions.

According to Dr. Cabrera, “Our goal is to integrate research with clinical care and the training of new professionals, to ensure that scientific progress has a real and positive impact on our patients’ health.”

The team joining Dr. Cabrera in this new stage includes doctors Josep Estadella, Alba Farres, Misericordia Guinot, Rocio Luna, Taisiia Melnychuk, Irene Mora, Josep Perelló, Marta Peró, and Ramon Rovira. Their joint work will strengthen Sant Pau’s commitment to research excellence and to generating knowledge that directly benefits women and society as a whole.

This new line of work will strengthen research in a field of high prevalence and direct impact on the quality of life of thousands of women. It will also promote the training of specialized professionals and collaboration with other national and international groups. Altogether, it aims to position IR Sant Pau as a leading center in biomedical research applied to women’s health. It highlights the importance of having research structures capable of anticipating healthcare challenges and translating scientific advances into the highest quality of care.

Researchers from the Sant Pau Research Institute (IR Sant Pau) and the Neurology Department of Hospital de Sant Pau have led a population-based study showing that urgent placement of a carotid stent during thrombectomy improves short- and long-term functional recovery in patients with acute ischemic stroke caused by tandem lesions. This is done without increasing hemorrhagic complications or mortality.

The study, published in Neurology, provides one of the strongest pieces of evidence to date on the role of carotid stenting in the acute management of stroke. Based on a cohort of 578 patients from the population-based Codi Ictus Catalunya registry, the research analyzes real-world practice across ten reference centers performing endovascular treatment in Catalonia between 2017 and 2023, making it both representative and clinically relevant.

Ischemic stroke remains one of the leading causes of death and disability worldwide. Recently, mechanical thrombectomy—a procedure that removes the clot blocking a cerebral artery—has become the treatment of choice for large intracranial artery occlusions. However, between 10% and 20% of patients present with tandem lesions, meaning a simultaneous blockage of the extracranial carotid artery and an intracranial artery. This situation, in addition to representing a particularly severe clinical scenario, poses a complex therapeutic challenge and has sparked debate regarding the safest and most effective revascularization strategy.

A Strategy with Clear Benefits

Although immediate removal of the intracerebral clot is critical for recovery, urgent treatment of the extracranial carotid artery is less straightforward. On one hand, treating the carotid artery immediately through stent placement may enhance the efficacy of thrombectomy and thus the patient’s functional recovery. On the other hand, the intensive antiplatelet therapy required to keep the stent open may increase the risk of intracerebral hemorrhage, which can be fatal. As a result, no standardized protocols currently exist for the acute treatment of these patients, who have traditionally shown worse recovery rates than other ischemic stroke cases.

The study, coordinated by Dr. Garbiñe Ezcurra-Díaz, researcher in the Cerebrovascular Diseases Group at IR Sant Pau, provides a robust answer to this controversy. The researchers found that immediate carotid revascularization with stenting is associated with better short- and long-term functional outcomes, without increasing hemorrhagic complications or mortality.

Our results show that urgent carotid stenting is not only safe but also consistently improves patients’ long-term functional independence,” explains Dr. Garbiñe Ezcurra-Díaz. “These findings reinforce the importance of considering immediate carotid revascularization in the context of thrombectomy, always within experienced teams and under strict antithrombotic management.”

Furthermore, the positive outcomes were consistent across different clinical profiles, supporting the applicability of the procedure in real-world practice. Functional improvement was even observed in patients with less severe carotid lesions, suggesting that the benefit may not be limited to the most complex cases and that this strategy could be more systematically integrated into acute stroke care for tandem lesions.

Better Functional Outcomes and Higher Recanalization Rates

Among the 578 patients included in the study, 59.5% were treated with urgent carotid stenting. In this group, outcomes were significantly better both in the acute phase and during follow-up. Patients who received a stent had a 1.5-fold higher likelihood of achieving better functional scores, as measured by the modified Rankin Scale (mRS), at both 90 days and one year after the stroke, compared with those who did not receive a stent.

Similarly, the successful recanalization rate—that is, complete restoration of cerebral blood flow—exceeded 90% among patients treated with urgent stenting, compared with 73% in those who were not. This finding confirms that simultaneous revascularization of both lesions increases the efficacy of endovascular treatment and improves overall cerebral perfusion, a key factor for preserving neuronal tissue and promoting functional recovery.

The study also assessed the impact of antithrombotic therapy on procedural safety. The results indicated that early administration of dual antiplatelet therapy (typically aspirin and clopidogrel) within the first 24 hours after the intervention was associated with lower mortality and better functional outcomes, without a significant increase in symptomatic intracranial hemorrhage. This finding is particularly relevant, as fear of hemorrhagic complications often discourages clinicians from performing urgent carotid stenting during thrombectomy.

According to Dr. Pol Camps, head of the Cerebrovascular Diseases Research Group at IR Sant Pau and senior author of the study, “This work reinforces the safety and efficacy of carotid stenting for the acute treatment of stroke with tandem lesions in real-world clinical practice. It is the largest population-based study conducted to date, providing strong external validity for the results.”

Statistical analyses adjusted for age, sex, and comorbidities confirmed the robustness of the findings, indicating that the benefit of carotid stenting is genuine and independent of other prognostic factors.

A Collaborative Population-Based Study

The study, named SECURIS (Stenting Extracranial Carotid Artery stenosis dURing endovascular treatment in patients with acute Ischemic Stroke), was developed from the Codi Ictus Catalunya (CICAT) registry, a mandatory population-based registry that prospectively collects all stroke cases treated within the Catalan hospital network. This registry, promoted by the Department of Health of the Government of Catalonia, is an essential tool for assessing healthcare quality and advancing clinical stroke research on a population scale.

The project involved collaboration among the ten reference centers in Catalonia with mechanical thrombectomy capability, including Hospital de Sant Pau, and brought together neurologists and neurointerventionists from across the region. This collaborative approach enabled the analysis of a large, representative cohort of real-world clinical practice, giving the study strong external validity and added value compared with previous, smaller, or single-center investigations.

“Having access to a population-based registry like CICAT allows us to obtain robust evidence on treatment effectiveness and safety under real-world conditions, which is crucial for guiding clinical decision-making and future practice guidelines,” emphasizes Dr. Pol Camps.

The SECURIS results strengthen the case for urgent carotid stenting as a complement to thrombectomy in patients with tandem lesions and open new research avenues. The authors highlight the need for randomized clinical trials to confirm these findings and to explore potential modulating factors of benefit, such as sex or age, since subgroup analysis suggested that the benefit of stenting was less pronounced in women and older patients.

The study also points to the opportunity to optimize antithrombotic protocols following urgent carotid revascularization, as patients treated with early dual antiplatelet therapy showed better outcomes without an increase in bleeding risk.

Article reference:

Ezcurra-Díaz G, Cardona P, Rodriguez-Villatoro N, Doncel-Moriano Cubero A, Flores-Pina B, Figueras-Aguirre GL, Fernández-Pérez I, Xuclà-Ferrarons T, Purroy F, Flores A, Guasch-Jiménez M, Lambea-Gil Á, Prats-Sanchez L, Ramos-Pachón A, Martinez-Domeño A, Marti-Fabregas J, Fernández-Vidal JM, Abilleira S, Salvat-Plana M, Núñez-Guillén A, Lara-Rodríguez B, Rodriguez-Luna D, Hernandez D, Rodríguez Vázquez A, Cabero-Arnold A, Menéndez Albarracín A, Cánovas D, Camps-Renom P. *Emergent carotid artery stenting in patients with acute ischemic stroke with tandem lesions: One-year follow-up results from the SECURIS study.* Neurology 2025;105:e214067. https://doi.org/10.1212/WNL.0000000000214067.

A new study published in the Journal of Hepatology shows that carvedilol, a non-cardioselective beta-blocker, is more effective than traditional beta-blockers in preventing complications of cirrhosis, both in compensated patients and in those with already decompensated disease. This is the first large-scale, head-to-head comparison between carvedilol and traditional non-selective beta-blockers such as propranolol and nadolol in this setting, providing strong evidence for clinical practice.

The study included 540 patients treated at six European hospitals between 2008 and 2021, with an average follow-up of three years in compensated patients and just over two and a half years in decompensated ones. Results indicated that carvedilol reduced the risk of a first decompensation by 39% in compensated patients and reduced the combined risk of new complications or death by 43% in decompensated patients. Moreover, the safety profile of carvedilol was comparable to that of the classical drugs.

This study was the result of collaboration among several Spanish groups of the Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD). These included the teams led by Drs. Juan Carlos García-Pagán (Hospital Clínic-IDIBAPS), José Luis Calleja (Hospital Puerta de Hierro), Rafael Bañares (Hospital Gregorio Marañón), Agustín Albillos (Hospital Ramón y Cajal), and the CIBER Cirrhosis Complications group at Hospital de Sant Pau, led by Dr. Germán Soriano and coordinated at the Research Institute Sant Pau (IR Sant Pau) by Drs. Edilmar Alvarado and Cándido Villanueva. Other international centers, such as the University of Vienna, also participated, further reinforcing the robustness and international relevance of the findings.

Dr. Edilmar Alvarado highlighted the importance of the results: “Decompensation marks a turning point in the course of cirrhosis, with a direct impact on patients’ quality of life and survival. Demonstrating that carvedilol provides superior protection represents a highly significant step forward for the clinical management of patients with both compensated and decompensated cirrhosis.”

From Classical Treatment to New Evidence

Liver cirrhosis is one of the leading causes of advanced liver disease and liver-related mortality worldwide. Its progression is usually silent until decompensation occurs—that is, when complications such as ascites (fluid accumulation in the abdomen), variceal bleeding, jaundice, or hepatic encephalopathy appear. From that point onward, the prognosis worsens considerably, and the risk of mortality and the need for liver transplantation increase.

The key factor behind these complications is the development of portal hypertension, an abnormal increase in pressure within the portal vein—the main blood vessel that carries blood from the intestines to the liver—caused by greater liver stiffness and increased blood flow within the portal circulation. This rise in pressure promotes the formation of varices in the esophagus and stomach, as well as ascites and other clinical events known as cirrhosis decompensations.

To control portal hypertension, non-selective beta-blockers (NSBBs), such as propranolol and nadolol, have been used for decades. These drugs reduce splanchnic blood flow—that is, blood from the digestive system flowing to the liver through the portal vein—and lower portal pressure, helping prevent complications. Carvedilol, in addition to blocking beta receptors, has an extra vasodilatory effect on alpha-1 receptors, leading to a greater reduction in portal pressure. This superior hemodynamic effect explains the higher potency of carvedilol as a beta-blocker and translates into the better clinical protection observed in the study.

A Shift in Clinical Practice

This finding has direct implications for the management of patients with cirrhosis. Carvedilol is now established as the reference treatment for preventing complications, not only in the early stages of the disease (compensated) but also in more advanced stages (decompensated). This means its use can delay disease progression, reduce the occurrence of decompensations and hospitalizations, and improve both survival and quality of life for patients.

Based on these results, carvedilol stands out as the non-cardioselective beta-blocker of choice for treating portal hypertension in patients with liver cirrhosis. Furthermore, the data support its broader inclusion in international clinical guidelines. The evidence generated by this study could help harmonize medical practice across countries and reduce inequalities in access to more effective treatments.

Spain has a long tradition in the study of portal hypertension and its complications, and this work confirms the leadership of national research groups in this field. Collaboration among reference hospitals and the Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD) has made it possible to assemble one of the largest and most representative cohorts to date. This strengthens Spain’s role as a driving force in hepatology research.

Dr. Alvarado concluded, “The magnitude of the data and the diversity of participating centers allow us to state that carvedilol is not only more effective but may also transform how we prevent cirrhosis complications in routine clinical practice.”

Reference Article:

Fortea JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, Hernández-Gea V, Aracil C, Llop E, Puente A, Roig C, Reiberger T, García-Pagan JC, Calleja JL, Ferrero-Gregori A, Mandorfer M, Villanueva C, Crespo J. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis. J Hepatol 2025;83:70–80. https://doi.org/10.1016/j.jhep.2024.12.017

The Sant Pau Research Institute (IR Sant Pau), a health research institute (IIS) accredited by the Instituto de Salud Carlos III (ISCIII), continues its commitment to primary care research with the incorporation of the Dreta de l’Eixample Primary Care Team (EAP). This is a new member of the consortium, in addition to the EAP Sardenya, which has been part of IR Sant Pau since its foundation. Together, the two institutions provide healthcare coverage for a population of 74,207 people. This addition strengthens research lines in epidemiology, public health, and primary care, reinforcing the institute’s commitment to improving population health through biomedical research and innovation of excellence applied to clinical practice.

According to Dr. Lluís Cuixart, Head of Research at EAP Dreta de l’Eixample, «this integration represents an opportunity for our institution to continue generating scientific knowledge from primary care and to contribute to public health research. We must not forget that primary care is often the gateway to the healthcare system, giving us a broader view of the population’s needs».

For Dr. Jordi Surrallés, Scientific Director of IR Sant Pau, «the incorporation of EAP Dreta de l’Eixample allows us to expand the scope of research in primary care, a key area for improving population health. It also enhances our capacity to develop clinical trials with a more integrated vision of healthcare».

EAP Dreta de l’Eixample, located in Barcelona’s Eixample district, has a multidisciplinary team that includes 31 physicians, 24 nurses, and more than 50 professionals from other healthcare disciplines. The team has already participated in national and international research projects such as the IBERICAN, APPRESO, APHOSDIAB-COVID, and DIAMOND studies. It has been one of the primary care centers with the highest number of communications at the Spanish Society of Family and Community Medicine (semFYC) National Congress of Family Medicine recently.

The center’s main research lines focus on cardiovascular diseases but also include studies on the most common conditions treated in primary care, such as diabetes, chronic obstructive pulmonary disease (COPD)/asthma, psychiatric disorders, and interventions aimed at improving pharmacological prescribing. The contribution of EAP Dreta de l’Eixample will strengthen IR Sant Pau’s primary care research lines, fostering new synergies and collaborations.

The collaboration will improve knowledge transfer between primary care and hospital services, enabling more efficient implementation of scientific advances into daily clinical practice. It is also expected to facilitate access for EAP Dreta de l’Eixample professionals to new training and collaboration opportunities with established research groups at IR Sant Pau.

This agreement comes at a time when primary care is gaining increasing prominence in the field of biomedical research. With this incorporation, IR Sant Pau consolidates its role as a leading institution in health research, promoting high-quality care based on scientific evidence.

Nanoligent, a spin-off from the Institut de Recerca Sant Pau (IR Sant Pau) and the Universitat Autnoma de Barcelona (UAB), has closed a €12 million funding round led by Inveready to advance the development of its oncology candidate NNL1524. The company hopes to complete its first evaluation in patients with solid tumors.

The transaction was led by Inveready Biotech IV and included participation from CDTI through the Innvierte program, Clave Capital, and existing investors i&i Biotech Fund I, Nanolinvest (an investment vehicle of members of Italian Angels for Growth and Doorway), and AVANTECA Partners.

The funds will be used to complete the regulatory preclinical development of NNL1524, initiate a Phase Ia clinical study in patients with solid tumors, and scale up production by optimizing manufacturing processes.

Research with Impact: From Sant Pau to the Patient

Nanoligent was founded as a spin-off of IR Sant Pau and UAB following a long-standing collaboration between the Oncogenesis and Antitumor Drugs Group at IR Sant Pau, led by Dr. Ramon Mangues, and the Nanobiotechnology Group at UAB’s Institute of Biotechnology and Biomedicine, co-directed by Drs. Antonio Villaverde and Esther Vázquez. Both groups are part of CIBER-BBN.

This research line at Sant Pau, focused on the CXCR4 target, builds on more than fifteen years of work aimed at developing nanomedicines capable of selectively directing therapeutic agents to tumor cells with high expression of this receptor. The center and UAB, together with CIBER, are also co-owners of joint patents related to targeted delivery methods for CXCR4-positive cells, resulting from this extensive research trajectory. Five of these patents have been licensed to Nanoligent and form the basis of this development.

«The case of Nanoligent demonstrates how the basic and translational research we conduct at Sant Pau can have a direct impact on the development of new cancer therapies,» says Dr. Ramon Mangues. «The knowledge generated in the laboratory has enabled the creation of a technology with enormous clinical potential and, at the same time, the establishment of a company that drives its translation to patients».

NNL1524: A Candidate Targeting a Key Driver of Metastasis

The candidate NNL1524 is a CXCR4-targeted cytotoxic nanoconjugate, a membrane receptor involved in tumorigenesis, cell proliferation, and metastasis, which is overexpressed in various hematologic cancers and solid tumors such as colon, lung, and breast cancer.

In preclinical models, NNL1524 has shown significant tumor regression as monotherapy and a favorable safety profile, reinforcing its potential as a new therapeutic option in areas with unmet clinical needs.

An Example of Knowledge Transfer

Nanoligent’s progress represents a tangible example of knowledge transfer from Sant Pau’s biomedical research to the biotechnology sector. The results generated by Dr. Mangues’ group have laid the foundation for a technology with real therapeutic potential, now being developed within a spin-off company with international projection.

About Nanoligent

Nanoligent is a biotechnology company specializing in the development of targeted nanodrugs for cancer treatment, based on a pioneering technological platform of protein–drug nanoconjugates. The company is led by Dr. Montserrat Cano (CEO) and Dr. Manuel Rodríguez (Chairman of the Board of Directors), both with extensive experience in drug development and biotechnology project management.

Dr. Íñigo Rodríguez Baz, from the Neurobiology of Dementias Group at the Sant Pau Research Institute and the Memory Unit at Hospital Sant Pau, has been awarded a grant from the Alzheimer’s Association. This support will enable the development of a project aimed at improving the biological diagnosis of neurodegenerative diseases that cause dementia.

The Alzheimer’s Association grants are awarded to researchers worldwide whose projects are of high quality and relevance to advancing knowledge of Alzheimer’s disease and related dementias. Receiving this distinction represents a mark of excellence for research at IR Sant Pau.

This support will strengthen and expand the pioneering work already being carried out at Sant Pau using the Seed Amplification Assay (SAA), an innovative technique that allows for the highly sensitive detection of alpha-synuclein in cerebrospinal fluid. This protein, when abnormally aggregated inside neurons, causes cell death and is associated with diseases such as dementia with Lewy bodies and Parkinson’s disease, although it can also be found in some cases of Alzheimer’s disease.

At Sant Pau, thanks to close collaboration between the Biochemistry Service and the Memory Unit, SAA is already being applied in research practice, positioning the hospital as a reference center in the development of biomarkers for synucleinopathies—neurodegenerative diseases in which the alpha-synuclein protein accumulates abnormally in the brain.

Until recently, alpha-synuclein was very difficult to detect, so diagnoses relied mainly on clinical evaluation. With SAA, implemented at Sant Pau by the Biochemistry Service, it is now possible to detect minimal amounts of misfolded alpha-synuclein. This technique will not only make it possible to identify the presence of the protein but also to analyze how it behaves in each disease and verify whether laboratory results match findings from autopsies, thus strengthening the biological diagnosis.

“This technique opens an extraordinary avenue for the early detection of these pathologies and for differentiating them from one another with greater precision,” explains Dr. Rodríguez Baz. “With our study, we aim to validate its use in a large cohort of patients and determine how it relates to other biomarkers from neuroimaging, fluid analysis, and reference neuropathological findings.”

The Sant Pau team will analyze more than 1,500 samples from individuals with different clinical profiles: patients with dementia with Lewy bodies, sporadic Alzheimer’s disease, Alzheimer’s disease associated with Down syndrome, and cognitively healthy older adults. In addition, the study will consider factors such as age, sex, genetics (apolipoprotein E), and ethnic background to better understand how they influence alpha-synuclein aggregation and the biological variability of these diseases. The project will last for three years, be mentored by Drs. Juan Fortea and Daniel Alcolea, and include collaboration from Dr. Mireia Tondo and Rosa Ferrer of the Biochemistry Service at Hospital Sant Pau, where the SAA analyses are carried out.

This work could also help distinguish between primary and secondary alpha-synuclein aggregations. In diseases known as synucleinopathies—such as dementia with Lewy bodies or Parkinson’s disease—the protein appears as a primary aggregation, meaning it is the main cause of brain damage. In contrast, in some cases of Alzheimer’s disease, it may appear as a secondary aggregation, accompanying other disease-related alterations. This distinction is crucial because the presence of secondary alpha-synuclein is associated with a worse prognosis, faster symptom progression, and greater challenges in developing effective treatments. Being able to identify this phenomenon early and accurately would represent a major step forward in understanding the disease and guiding therapeutic strategies.

Furthermore, this project aims to fill key gaps in current research by providing new biomarkers, refining disease stratification, and improving understanding of mixed forms of dementia in which different pathological processes converge.

This pioneering research could mark a turning point in the way dementia is diagnosed, enabling earlier and more accurate diagnoses, better patient selection for clinical trials, and more effective development of personalized therapies. “Our ultimate goal is for patients to receive the correct diagnosis sooner and, with it, the most appropriate treatment and care,” says Dr. Rodríguez Baz.

The Ophthalmology Department of Hospital de Sant Pau, together with the Ophthalmology Research Group of the Sant Pau Research Institute (IR Sant Pau), has recently participated in an international clinical trial of gene therapy for age-related macular degeneration (AMD) in its wet form, one of the leading causes of vision loss in older adults.

The procedure was carried out a few weeks ago and marked a milestone for the hospital, becoming the first surgery of its kind performed in Catalonia as part of the trial. The operation was completed without complications and marks the beginning of Sant Pau’s participation in this international phase 3 study, which is evaluating the efficacy and safety of the drug ABBV-RGX-314. “This is an innovative surgery in which we deliver the drug beneath the retina. The procedure went well, and we are now in the patient follow-up phase,” explains Dr. Ignacio Vela, principal investigator of the study at Sant Pau.

A Common Disease of Aging

AMD is a degenerative retinal disease that affects central vision, making everyday tasks such as reading, recognizing faces, or handling money difficult. Although it does not cause total blindness, it significantly limits the independence of those impacted. It is estimated that between 4% and 8% of people over 70 years old suffer from this disease, whose incidence continues to rise as life expectancy increases.

There are two main forms of AMD: dry and wet. The dry form, which accounts for most cases, progresses slowly and currently has no effective treatment in clinical practice, though several trials are underway. The wet form, on the other hand, progresses much faster and can cause significant vision loss within a few months if left untreated.

Current Treatments and Their Limitations

Since 2006, the standard treatment for wet AMD has consisted of intravitreal injections of antiangiogenic drugs, which block the proliferation of abnormal blood vessels beneath the retina and prevent fluid or blood from leaking into the macula. Thanks to these drugs, thousands of patients have managed to slow the progression of the disease and preserve part of their vision for years. At the time, they represented a major breakthrough in the management of this condition, which until then almost inevitably led to severe visual loss in a very short period.

Despite their effectiveness, this approach has important limitations. The treatment requires a very intensive schedule: during the first year, patients usually receive six to eight injections, followed by ongoing treatments every two or three months for the rest of their lives. Each of these visits involves injecting the medication directly into the eye, which causes anxiety and discomfort—especially among older adults who often have other chronic conditions. Moreover, each procedure carries a small risk of complications, such as infection or ocular inflammation, which requires careful monitoring.

“We manage to stop vision loss, but at the cost of highly demanding treatments for both patients and the healthcare system. The idea behind gene therapy is precisely to avoid this dependence on continuous injections into the eye,” notes Dr. Vela.

A New Approach: Gene Therapy

The new approach seeks to overcome these limitations with a different strategy: enabling the eye itself to continuously produce the substance that controls the disease. Instead of relying on periodic injections to deliver the drug externally, gene therapy aims for retinal cells to produce the antiangiogenic protein on their own, creating a treatment “from within” that acts consistently and stably over time.

“What’s new here is that with a single surgery, the eye could continuously produce the medication we currently administer through injections. It’s an entirely different concept with great potential,” says the Sant Pau researcher.

This approach has not only medical implications but also social and economic ones. If the therapy works as expected, it could significantly reduce the burden of care by decreasing hospital visits and the need for repeated procedures. At the same time, it could improve patients’ quality of life by freeing them from the anxiety and impact associated with frequent injections. Although still an experimental strategy and pending confirmation of results, the potential of this approach makes it one of the most promising research avenues in the fight against wet AMD.

The procedure involves a microincision eye surgery in which the investigational drug ABBV-RGX-314 is delivered beneath the retina. This gene therapy drug uses a viral vector to carry a therapeutic gene. Once inside retinal cells, this gene enables them to produce a protein with an antiangiogenic effect, similar to the one found in already-approved medications.

The procedure requires extreme precision, as the medication must be placed exactly in the subretinal space and in a specific dose. To ensure safety and proper administration, international specialists oversee the entire process in the initial cases—from the storage of the product in the pharmacy to the moment of injection in the operating room.

An International Clinical Trial

The study is currently in phase 3 and includes about 500 patients worldwide. In Spain, around ten centers are participating, although each has been able to recruit only a very limited number of patients due to strict inclusion criteria. In Catalonia, Sant Pau has been the only hospital to perform the gene therapy surgery, while other centers have been assigned to the control arm with conventional injections.

The trial compares three groups of patients: two treated with gene therapy at different doses and a third continuing with standard treatment. Recruitment has now closed, and the one-year follow-up phase is underway to determine whether patients require fewer injections than before and, above all, to assess the safety and efficacy of this new strategy.

“We now have to wait for the results. It’s important to emphasize that this is not an available treatment, but an ongoing clinical trial. The expectation is that it may reduce the need for injections and improve patients’ quality of life, but we don’t yet know if it will work, and we must remain cautious,” stresses Dr. Vela.

A Door of Hope, with Caution

The procedure performed at Sant Pau took place a few weeks ago, and the initial follow-up is positive, though it is still too early to assess results. “We need to wait at least one year of follow-up and then review the overall study findings. Until then, what we can highlight is the importance of Sant Pau’s participation in this pioneering international research,” notes the specialist.

Macular degeneration is an increasing problem in aging societies such as ours, and having innovative alternatives like gene therapy represents an opportunity that must always be pursued with scientific rigor. Participation in this trial reinforces the institution’s commitment to innovation in ophthalmology and contributes to advancing the development of future solutions for a disease whose prevalence continues to grow as the population ages.

The Sant Pau Research Institute (IR Sant Pau) and the CADASIL Spain Association (ACE) have strengthened their collaboration with a new contribution of 15,000 euros. This is aimed at advancing the research being carried out at the center on CADASIL, a hereditary disease that affects the small blood vessels in the brain and can cause recurrent strokes, severe migraines, cognitive impairments, and mood disorders.

This new donation, which adds to those made in previous years, highlights ACE’s commitment to biomedical research and to the work of the scientific teams striving to improve the diagnosis and treatment of this rare disease.

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a condition caused by mutations in the NOTCH3 gene, which alter the structure of the walls of cerebral blood vessels and impair blood flow. Despite advances in understanding its genetic basis and mechanisms of progression, no curative treatment currently exists, and clinical management is primarily focused on controlling symptoms and vascular risk factors.

The new financial contribution will help advance a drug repurposing project being developed by the Pharmacogenomics and Neurovascular Genetics Research Group at IR Sant Pau, led by Dr. Israel Fernández. The team focuses on identifying drugs already approved for other indications that may have a beneficial effect in CADASIL. This strategy helps reduce research time and costs, as it builds on compounds that have already demonstrated safety in humans. The ultimate goal is to discover new therapeutic pathways that could slow down or reverse the progression of the disease.

With this new contribution, ACE continues a collaboration that has been ongoing for years with IR Sant Pau. Over this time, the association has consistently supported the funding of various research lines related to the genetic, molecular, and clinical understanding of CADASIL. This has facilitated the acquisition of materials, the performance of specific analyses, and participation in national and international collaborative projects.

This continued involvement has made it possible to keep research on this rare disease active, where available resources are often limited, and has strengthened a relationship of trust and cooperation between ACE and the IR Sant Pau scientific team. Thanks to this support, researchers have been able to generate results that contribute to a more profound understanding of the disease mechanisms and to guide new therapeutic research directions.

IR Sant Pau deeply appreciates the trust and support of ACE, which are essential for advancing scientific knowledge and promoting new strategies for CADASIL, with the goal of improving the quality of life of affected individuals and their families.

An international team of researchers has demonstrated that the tetravalent dengue vaccine Qdenga provides significant protection against the disease under real-world conditions during the major 2024 epidemic in São Paulo, Brazil. The study, published in the journal The Lancet Infectious Diseases and led by Dr. Otavio Ranzani, head of the DataHealth Lab group at the Sant Pau Research Institute (IR Sant Pau). Together with Dr. Julio Croda, Fiocruz, Brazil, provides the first evidence of the vaccine’s effectiveness following its approval.

Dengue is one of the fastest-growing mosquito-borne viral diseases worldwide, driven by climate change and the spread of the Aedes mosquito. Each year it causes millions of infections in tropical and subtropical regions, and more outbreaks are being detected in non-endemic areas, such as Europe. In this context, having effective vaccines with solid real-world effectiveness data is an urgent public health need.

A Groundbreaking Study Conducted Amid an Epidemic

The study was carried out in the state of São Paulo, the epicenter of the 2024 dengue epidemic, which recorded tens of thousands of cases. Health authorities decided to prioritize vaccination in adolescents aged 10 to 14, since in endemic areas this age group accounts for a large proportion of symptomatic cases and faces a considerable risk of hospitalization. This age range is also consistent with the current WHO vaccination recommendation. In addition, this group is highly exposed to the mosquito vector due to their daily activities and mobility, which increases the likelihood of infection. In this context, an immunization campaign was launched that, over the course of the year, administered nearly 690,000 doses of Qdenga.

The research team analyzed more than 90,000 adolescents who presented with acute fever and underwent specific laboratory tests (NS1 antigen detection or PCR). Using a design known as test-negative case-control, they compared the proportion of vaccinated individuals among those who tested positive for dengue and those who tested negative, allowing estimation of the real-world effectiveness of the vaccine under everyday conditions.

Results showed that after a single dose, the vaccine reduced symptomatic dengue cases by around 50% with the first dose and by 62% with the second, and hospitalizations by 68%. Protection began 14 days after the first dose, was maintained during the first three months, and then declined, reinforcing the importance of completing the recommended and approved two-dose schedule for longer-lasting protection.

“This study design allowed us to quickly and accurately evaluate the vaccine’s effectiveness amid an epidemic, using real patient data from the healthcare system. It is a powerful approach to generate evidence in health emergencies,” explained Dr. Ranzani.

A Robust Study, Though With Some Limitations

The study has several strengths that reinforce the validity of its results. It is the first evaluation of the Qdenga vaccine under real-world conditions, beyond clinical trials, and was conducted in an exceptional context: a major dengue epidemic in São Paulo. The large number of adolescents included in the analysis enabled robust estimates of effectiveness, while the use of a test-negative case-control design reduced the risk of biases related to healthcare-seeking behavior. In addition, results remained consistent across different analytical methods, providing greater confidence in the conclusions.

However, the authors also noted some limitations that should be considered. Vaccine coverage achieved was relatively low, which limited the study’s power to analyze effectiveness after the second dose in detail. Information on prior dengue immunity among adolescents was also unavailable. Finally, serotype circulation during the outbreak was concentrated on DENV-1 and DENV-2, preventing evaluation of effectiveness against all four virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).

“Although the study has some limitations, the findings consistently show that Qdenga protects against dengue and reduces the risk of hospitalization. These data will be critical in guiding countries’ vaccination decisions,” emphasized Dr. Ranzani.

International and European Relevance

Until now, evidence on the vaccine was based solely on controlled phase 3 clinical trials. This new study is the first to demonstrate its impact on the general population under real-world conditions, in the midst of a major epidemic, reinforcing its value for public health decision-making.

Although Europe is not an endemic region, the spread of the Aedes mosquito linked to climate change has favored the emergence of local dengue outbreaks in countries such as France and Italy, while imported cases among travelers continue to rise. Catalonia is an example of this trend: between 2022 and 2024, more than 500 imported dengue cases were reported, mainly in people who had traveled to endemic regions. However, episodes of local transmission have already been detected, with two cases in 2018–2019, one in 2022, and an outbreak in 2024.

“Although in Catalonia and Europe most cases are still imported, the risk of local transmission is increasing. Having effective vaccines like Qdenga can make a difference in responding to future outbreaks and protecting travelers,” said Dr. Ranzani.

Public Health Implications

The results of this study are highly practical. On one hand, they support the use of Qdenga in emergency campaigns in endemic countries, where dengue outbreaks can quickly overwhelm health systems and cause a high number of hospitalizations. Evidence indicates that a single dose already provides significant protection within a few weeks, making the vaccine a key tool to curb ongoing epidemics and reduce hospital burden.

On the other hand, the data are also relevant for non-endemic countries, where most cases are imported but the risk of local transmission is increasing. In this context, the vaccine may play an essential role in traveler prophylaxis and in the prevention of autochthonous outbreaks, strengthening health system preparedness against the spread of the Aedes mosquito.

“The message is clear: the vaccine works and can protect against both mild and severe dengue. But to ensure sustained protection, we must complete the vaccination schedule. Our results can help policymakers and regulatory agencies better plan vaccination strategies,” added Dr. Ranzani.

The study was funded by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) in Brazil and involved an international group of researchers, including collaborators from the United States, in partnership with the São Paulo State Health Department.

A New Research Group at IR Sant Pau

This study is part of the first investigations of the DataHealth Lab, a newly established group at IR Sant Pau under the direction of Dr. Otavio Ranzani. Its creation responds to the need for teams capable of generating scientific evidence that is not only methodologically rigorous but also has a tangible impact on population health and public policy.

The DataHealth Lab is built on three main pillars: Epidemiology, Data Science, and Implementation Science. From this multidisciplinary perspective, the group addresses some of the most pressing challenges in global health. These include the effects of climate change and exposure to environmental pollutants on health, the growing threat of respiratory and emerging infections, the impact of antimicrobial resistance on health systems, and the improvement of critical care. Another key focus is the evaluation of the real-world effectiveness of vaccines, a line of work directly connected to the newly published study on the dengue vaccine.

The lab is also committed to innovation in critical care, exploring new strategies such as adaptive clinical trials, the use of telemedicine to improve care under high-pressure conditions, and the integration of artificial intelligence tools to support clinical decision-making. All this is pursued with a vision of open, inclusive, and sustainable science, oriented toward generating knowledge useful to society and health systems.

With the creation of the DataHealth Lab, IR Sant Pau strengthens its leadership in biomedical research and consolidates its role as a benchmark in the use of advanced data to tackle major public health challenges nationally and internationally.

Article Reference:

Ranzani OT, Lazar Neto F, Mareto LK, Brumatti TS, de Oliveira RD, da Silva PV, dos Santos ER, D’Agostini TL, De Paula RAC, Dean NE, Ko AI, Cummings DAT, Andrews JR, Hitchings MDT, Croda J. Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study. *Lancet Infect Dis* 2025. https://doi.org/10.1016/s1473-3099(25)00382-2

Dr. Saül Martínez-Horta, researcher at the Sant Pau Research Institute and neuropsychologist in the Movement Disorders Unit of the Neurology Department at Sant Pau Hospital, has been appointed the new Coordinator of the Neuropsychology Section of the Spanish Society of Neurology (SEN). This appointment represents recognition of both his clinical and research career as well as the growing role that neuropsychology plays within neurology.

The SEN, founded in 1949, is the leading scientific entity in neurology in Spain. With nearly 4,000 members, its mission is to promote scientific and clinical progress in neurology, foster continuing education for professionals, improve patient care for those with neurological diseases, and encourage research and outreach to advance the neurological health of the population.

Within this society, the Neuropsychology Section —created in 2012— aims to strengthen the presence of the discipline in the neurological field. Its main lines of action include developing specialized training programs, creating a nationwide map of neuropsychology, accrediting professional activity, drafting its manuals and guidelines, and establishing collaboration agreements that foster research and clinical practice.

Neuropsychology has undergone remarkable progress recently, driven by several factors: advances in neuroimaging, technologies applied to assessment, the development of new treatments for neurological diseases, and increasingly precise identification of prodromal and asymptomatic phases of neurodegenerative processes. In this context, the new leadership of the Section faces challenges focused on consolidating professional recognition, promoting multicenter research, and transferring knowledge into daily clinical practice.

According to Dr. Martínez-Horta, “this appointment is also a collective responsibility: neuropsychology must continue to grow hand in hand with neurology, and this is only possible through collaboration among professionals and institutions.” He adds, “our goal is for neuropsychology to be seen not only as an assessment tool but as a key element in understanding and comprehensively addressing neurological diseases.”

This appointment is also a source of pride for the Sant Pau Research Institute and Sant Pau Hospital, which congratulate Dr. Martnez-Horta on this new responsibility. They wish him great success in a stage that will further strengthen the role of neuropsychology in Spanish neurology.

For the third consecutive year, Club Natació Banyoles (CN Banyoles) has made a donation to the Sant Pau Research Institute to support the project dedicated to the study of Ewing Sarcoma, a rare type of cancer that mainly affects children and adolescents.

The funds come from the Marc Riera Castellà Memorial, a charity water polo tournament organized by the club in memory of Marc Riera, a young athlete who lost his life to this disease. All proceeds from the tournament have been allocated to support the research being carried out at Sant Pau.

A project born from solidarity

The Ewing Sarcoma research project was launched thanks to the initiative of Marc’s family and the charity race Arriarem, which mobilized hundreds of people to raise funds and raise awareness about the disease. Since then, various activities and organizations have joined the cause, consolidating a community-driven movement that has already raised over €100,000 for research.

In the case of the Marc Riera Castellà Memorial, the latest edition held in 2025 raised €6,000. Altogether, over its three editions, Club Natació Banyoles has contributed €11,500 to the Sant Pau project.

Research focused on patients’ quality of life

The project, led by Dr. Raúl Terés, Dr. Ana Sebio, and Dr. María Aguado, researchers from the Clinical Oncology Group at IR Sant Pau, aims to analyze the impact of treatments on patients’ quality of life, addressing physical, psychological, social, occupational, and reproductive aspects.

This line of research is pioneering because it not only studies therapeutic effectiveness but also the overall well-being of patients, with the goal of developing strategies to improve life after treatment.

Those who wish can continue supporting this project through the website.

The ultimate goal of the project is to reach €150,000, which will be fully allocated to this line of research.

Mariona’s Adventure has arrived at the Barcelona Zoo with resounding success. All the scheduled workshops were fully booked, and participants enjoyed a day of scientific discovery in a unique setting where biomedical research and environmental education came together. Held on Saturday, September 27, this mission marked a major highlight of the project’s second edition, as for the first time it moved beyond Tibidabo Amusement Park to reach another emblematic space in the city. The goal is to expand outreach settings and grow the community that accompanies Mariona in her scientific adventures.

This mission was dedicated to the nervous system and was carried out in collaboration with both the science communication team of IR Sant Pau and the educational staff of the Barcelona Zoo. They joined forces to offer a complete and enriching experience. IR Sant Pau professionals prepared interactive workshops to explain in a simple and engaging way how the brain works and which structures are part of the nervous system. Through games such as science bingo and assembling a paper puzzle, children learned playfully about the functions that allow us to think, feel, and move. They also had the chance to see and handle 3D models of real brains—an experience that helped them better understand the size and characteristics of this organ, as well as the changes it undergoes when it becomes ill and its cells stop functioning. In addition, outdoors, a giant science memory game challenged the memory of both children and adults, turning learning into a collective and participatory game.

Meanwhile, the zoo’s educational team contributed their expertise to explain the role of the nervous system in the animal world. Through their outreach work and the zoo animals themselves, they showed how the senses are essential for survival and adaptation in each species. Families were able to closely observe examples demonstrating how night vision, smell, or enhanced hearing are key to communication and defense in animals in their natural habitats.

In this way, science and nature came together in a privileged setting, creating an immersive experience that allowed participants to discover the complexity and beauty of the nervous system in both humans and animals. The activity reinforced the idea that scientific research and environmental education share a common goal: fostering curiosity, knowledge, and respect for life.

You can find more information on the website:

https://www.santpau.cat/es/web/public/mariona-investigadora

The Mariona Project

The “Mariona Investigadora” project is an educational and outreach initiative developed by IR Sant Pau. Mariona is a character that symbolizes an eight-year-old girl passionate about science and medicine, whose purpose is to inspire children and young people to explore the world of scientific research. It is precisely at this age—around eight years old—that girls often begin to lose interest in science, due to persistent stereotypes and the lack of role models. This project seeks to address that gap.

Through a series of missions and challenges designed to be carried out at Tibidabo Amusement Park and at the Barcelona Zoo, Mariona encourages children to discover the secrets of the human body. They take part in scientific experiments and learn about the importance of adopting a healthy lifestyle.

The project also highlights the role of women in science, showcasing real examples of female researchers who share their professional and personal experiences to promote gender equality in this field.

Science With a Gender Perspective

IR Sant Pau continuously fosters dialogue with society, aligned with its RRI plan and with its objectives for Scientific Education and Public Engagement. As a CERCA center and as a Scientific Culture and Innovation Unit accredited by FECYT, it has a strong commitment to bringing research closer to society. As the only research institute in Catalonia with a transversal gender research program, IR Sant Pau serves as a spokesperson for the latest scientific advances. It underscores the importance of conducting research with a gender perspective and promoting the role of women in research and the future of science.

Upcoming Activities in the Second Edition:

• November 22, 2025 – Tibidabo Amusement Park: Mission on the respiratory system
• February 15, 2026 – Grand finale at Tibidabo Amusement Park coinciding with the International Day of Women and Girls in Science

On the occasion of Familial Hypercholesterolemia (FH) Awareness Day, the Sant Pau Research Institute (IR Sant Pau) highlights its commitment to biomedical research aimed at improving the diagnosis and treatment of this highly prevalent genetic disease with a strong impact on cardiovascular health.

Heterozygous familial hypercholesterolemia (FH) is a genetic disorder that affects approximately 1 in 250 people. It is transmitted in an autosomal dominant manner, meaning that inheriting a single altered copy of the gene from one parent is sufficient to develop the disease. It is caused by mutations in key genes of lipid metabolism, such as LDLR, APOB, or PCSK9, which regulate how the body clears LDL cholesterol, commonly known as “bad cholesterol.”

Under normal conditions, the liver removes this cholesterol from the blood and clears it from circulation. This clearance process is essential for maintaining healthy levels. However, in individuals with FH, the clearance mechanism is impaired, leading to excessive LDL cholesterol accumulation in the blood from birth. This buildup significantly increases the risk of developing premature atherosclerotic cardiovascular disease, such as myocardial infarction or angina, at much earlier ages than in the general population—even before the age of forty.

Despite its frequency, FH remains underdiagnosed. It is estimated that fewer than 20% of cases are identified, representing a major missed prevention opportunity. Moreover, even among diagnosed patients, there are wide variations in treatment intensity and adequacy, which negatively impact long-term prognosis.

SAFEHEART: An International Reference Cohort for FH Research

IR Sant Pau actively participates in SAFEHEART, a nationwide, prospective, multicenter cohort in Spain that conducts clinical, lipid, and genetic follow-up of individuals with FH. SAFEHEART was launched in 2004 by the Familial Hypercholesterolemia Foundation, which has since promoted, managed, and coordinated it under the leadership of Dr. Pedro Mata. With more than 4,000 genetically confirmed patients, it is the largest and best-characterized registry of this disease worldwide. Over the years, this cohort has generated numerous reference studies to better understand the natural history of FH and improve clinical management.

One of the most recent studies from this cohort has analyzed in depth the differences between men and women in lifetime burden of atherosclerotic cardiovascular disease. The analysis, involving Dr. Teresa Padró, head of the Cardiovascular Disease Evolution Biomarkers Group at IR Sant Pau and member of the CIBER of Cardiovascular Diseases (CIBERCV), aimed to determine the extent to which sex influences cardiovascular risk. It also sought to determine the age of event onset in people with FH. The results were published in The Lancet Diabetes & Endocrinology.

“Having access to such a well-characterized cohort as SAFEHEART, with over a decade of follow-up and genetically confirmed diagnoses, has allowed us for the first time to robustly analyze how sex influences the cardiovascular prognosis of these patients,” emphasized Dr. Padró.

Women With FH Show Better Clinical Outcomes

The findings are conclusive. Over the follow-up period, women with FH showed a significantly lower risk of cardiovascular events compared to men. Moreover, when these events did occur, they did so at older ages. The mean age of onset of the first cardiovascular event was 61.6 years in women compared with 50.6 years in men. This more than decade-long difference remained even after adjusting for age, family history, traditional risk factors such as hypertension, diabetes, or smoking, as well as lipid profile and type of treatment received.

In terms of event-free survival from major cardiovascular outcomes, such as myocardial infarction, stroke, or coronary revascularization, women also fared better. While the median age of the first event in men was 55.5 years, in women this was delayed until 74.9 years. Thus, the probability of remaining free of cardiovascular disease from birth was considerably higher in the female group.

“Women not only experience fewer cardiovascular events, but these occur later in life. This forces us to reflect on the possible biological bases of this protection and, at the same time, on the biases that still exist in clinical care,” noted Dr. Padró.

Although both men and women achieved similar reductions in LDL cholesterol during follow-up, men more frequently received high-intensity statin combinations with ezetimibe or PCSK9 inhibitors, indicating differences in therapeutic strategies applied according to patient sex. Nevertheless, women with FH in the SAFEHEART cohort showed a lower incidence of coronary disease and lower cardiovascular mortality during follow-up.

These differences may be partly explained by intrinsic biological factors, such as higher HDL cholesterol levels in women, the protective effect of sex hormones before menopause, or lower overall atherosclerotic burden at younger ages.

“The combination of protective biological factors and clinical factors yet to be fully addressed should encourage us to consider more personalized treatment strategies. We cannot assume cardiovascular risk is the same for all patients with FH. Incorporating the sex perspective into clinical practice is essential,” said the IR Sant Pau researcher.

IR Sant Pau Research Drives More Personalized and Equitable Medicine

For years, IR Sant Pau has worked to promote cardiovascular medicine based on risk stratification and personalized clinical decision-making. In the case of FH, this vision involves not only early detection of carriers of pathogenic genetic mutations but also tailoring treatment to each patient’s individual profile, considering clinical, biological, and social characteristics, including sex.

IR Sant Pau’s contribution to the SAFEHEART cohort reinforces the institution’s commitment to translational research that directly impacts clinical practice and public health. Through multidisciplinary teams, collaborative networks, and a comprehensive approach to patient care, the center contributes to advancing knowledge, management, and prognosis of preventable cardiovascular diseases.

“Our goal as researchers is that no patient with FH goes unidentified and untreated. At the same time, we aim to ensure that treatment is the most appropriate for each individual. This is the foundation of medicine that is fairer, more effective, and more humane,” concluded Dr. Padró.

Article Reference:

de Isla LP, Vallejo-Vaz AJ, Watts GF, Muñiz-Grijalvo O, Alonso R, Diaz-Diaz JL, Arroyo-Olivares R, Aguado R, Argueso R, Mauri M, Romero MJ, Álvarez-Baños P, Mañas D, Cepeda JM, Gonzalez-Bustos P, Casañas M, Michan A, Muñoz-Torrero JFS, Faedo C, Barba MA, Dieguez M, de Andrés R, Hernandez AM, Gonzalez-Estrada A, Padró T, Fuentes F, Badimon L, Mata P, SAFEHEART Investigators. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study. Lancet Diabetes Endocrinol 2024;12:643–52. https://doi.org/10.1016/S2213-8587(24)00192-X

The Sant Pau Research Institute (IR Sant Pau) has been selected in the CaixaImpulse 2025 call by the “la Caixa” Foundation to promote an innovative project in the field of cardiology. This project is led by Dr. Dabit Arzamendi and Dr. Abdel Hakim from Sant Pau Hospital, together with Dr. Oscar Camara from Pompeu Fabra University (UPF).

Procedures such as valve replacement or left atrial appendage closure can cause leaks when implanted devices do not optimally fit the patient’s anatomy. These leaks are serious, as they can lead to heart failure, stroke, or damage to blood cells, with a strong impact on quality of life. Currently available devices are standardized and manufactured in a limited number of sizes, which often prevents a precise fit.

The project proposes a new strategy based on personalized medicine, using advanced 3D modeling and virtual simulations to design custom-made devices tailored to each patient. The methodology involves creating a digital model of the heart, assessing the extent and behavior of the leaks, and developing specific solutions that allow for more effective and lasting sealing. This approach is expected to reduce risks such as clot formation, avoid repeated interventions, and improve recovery.

In an initial phase, the team will validate the devices through simulations and imaging techniques, with the goal of optimizing the designs and demonstrating their effectiveness under realistic conditions. The ultimate purpose is to improve clinical outcomes and provide greater quality of life for patients with complications following the implantation of cardiac devices.

According to Dr. Dabit Arzamendi, “Our goal is to bring truly personalized solutions into the clinical setting that respond to each patient’s anatomy. We believe this approach will reduce serious complications and significantly improve recovery and quality of life for affected individuals.”

CaixaImpulse 2025: Biomedical Innovation With Impact

The CaixaImpulse 2025 call aims to accelerate the arrival of innovations in biomedicine and health to the market, supporting projects that address unmet clinical needs and fostering the creation of science-based products, services, and companies.

In this edition, the “la Caixa” Foundation has allocated €3.8 million to promote 31 biomedical projects from research centers, hospitals, and universities in Spain and Portugal. The call received a total of 428 applications, evaluated by international panels of experts in health innovation.

The selected projects are distributed across different areas: 14 in the field of therapies, 12 in medical devices, 4 in diagnostics, and 1 in digital health. Depending on their level of maturity, initiatives receive funding ranging from €50,000 to €500,000 and can advance to later phases as they reach development milestones.

In addition to financial support, CaixaImpulse offers participating teams specialized training, mentorship, and expert guidance in key areas such as technology transfer, intellectual property, exploitation strategies, and access to investors.

Since its launch in 2015, CaixaImpulse has supported 263 projects, contributed to the creation of 54 spin-offs, and helped raise more than €180 million in additional funding from investors and competitive calls.

The approval of new antibody-based drugs for Alzheimer’s disease—lecanemab and donanemab—and of blood-based diagnostic tests marks the beginning of a new era in the diagnosis and treatment of this condition. However, without swift reforms in healthcare systems, public policies, and social attitudes, their full potential will not be realized, warn 40 leading Alzheimer’s experts in The Lancet Series on Alzheimer’s disease.

Alzheimer’s disease accounts for approximately 70% of all dementia cases and is one of the leading causes of disability, resulting in high social and economic costs.

In a novel comparison, the series highlights that new monoclonal antibody treatments can slow the progression of Alzheimer’s disease to a level comparable with the effectiveness of drugs used in cancer, rheumatoid arthritis, and multiple sclerosis. Nonetheless, the authors note that differences in patient age, clinical outcomes, and side effects mean these comparisons must be interpreted with caution.

Despite the similarity in treatment effectiveness for other diseases, the high costs of the drugs, the complex requirements of diagnostic testing, suboptimal attention to behavioral symptoms, and insufficient resources threaten to leave Alzheimer’s patients behind.

Encouragingly, improvements in Alzheimer’s disease prevention are also on the horizon, with the emergence of Brain Health Services, which identify people at high risk of developing the disease and provide them with personalized treatment programs. However, most Alzheimer’s cases occur in individuals at low or normal risk, making population-level measures that reduce risk—such as healthier urban design and restrictions on alcohol and sugary drinks—essential.

The authors call for coordinated global action to ensure that rapid scientific progress in the field of Alzheimer’s disease is matched by reforms in healthcare provision, policies, and society.

Among the series’ authors are two Spanish researchers: Dr. Juan Fortea, from the Sant Pau Research Institute (IR Sant Pau) and head of the Sant Pau Memory Unit, and Dr. Eider Arenaza-Urquijo, from ISGlobal. Both contributed to the section on diagnosis, a field currently undergoing a true revolution thanks to the arrival of blood biomarkers. These tests make it possible to detect biological changes of Alzheimer’s even before the first clinical symptoms appear, opening the door to interventions at very early stages of the disease and maximizing the impact of new treatments.

In Dr. Fortea’s words, “We are witnessing a milestone in the treatment of Alzheimer’s with the first drugs capable of modifying the course of the disease. This breakthrough makes continued progress in diagnosis even more significant and important, especially with the development of biomarkers that allow us to identify patients in the earliest stages. Only then can we ensure that new treatments are administered at the right time and have the greatest possible benefit for patients.”

The lead author of the series, Professor Giovanni Frisoni from the University of Geneva (Switzerland), states, “Blood tests, biological drugs for Alzheimer’s disease, and preventive interventions are shifting care into an entirely new and exciting landscape. However, patients’ longstanding needs will not disappear. On the contrary, more primary care physicians and dementia specialists will need to master the less flashy but steady advances made over recent decades in the care and treatment of behavioral disorders. This includes the use of sophisticated imaging and laboratory diagnostic tools, and psychosocial care. A concerted societal effort in this direction will ensure that our current and future patients fully benefit from the potential of scientific and technological advances.”

To access the articles, visit:

https://www.thelancet.com/series-do/alzheimers-disease

Cancer continues to be one of the leading causes of death worldwide and in Spain. According to the report Cancer Figures in Spain 2025 by the Spanish Society of Medical Oncology (SEOM), nearly 300,000 new cases of cancer will be diagnosed in Spain this year, with colorectal, breast, lung, prostate, bladder, lymphoma, and myeloma being the most common. In 2023, tumors accounted for more than a quarter of all deaths in Spain (26.5%), with 115,889 deaths, placing them practically at the same level as cardiovascular diseases as the leading cause of mortality.

Despite these figures, research has enabled survival to improve significantly. Five-year net survival now reaches 55.3% in men and 61.7% in women, nearly double the rate of four decades ago. These advances are due both to earlier diagnosis—which allows treatment of the disease in its initial stages—and to the development of increasingly effective and personalized therapies.

Immunotherapy and CAR-T Therapies: A New Horizon

Among the most innovative treatments that have transformed cancer care is immunotherapy, which harnesses the patient’s immune system to recognize and destroy tumor cells. One of the most promising modalities is CAR-T therapy, which genetically modifies the patient’s T lymphocytes to specifically and more effectively target and eliminate tumor cells.

The Sant Pau Research Institute (IR Sant Pau) is one of the few centers in Europe to develop, academically and independently—without pharmaceutical industry support—two CAR-T therapies:

• HSP-CAR19M, directed at B-cell lymphomas via the CD19 antigen, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. It is enriched with memory T cells to ensure durability and is being developed within the TERAV network of the Instituto de Salud Carlos III.
• HSP-CAR30, targeting the CD30 antigen, focused on classical Hodgkin lymphoma and other CD30⁺ tumors. It is the first academic European CAR-T therapy against this target, also designed with memory T cells to reinforce efficacy and persistence.

The most recent major achievement in this line of research has been the highly positive results in patients with refractory Hodgkin lymphoma treated with HSP-CAR30. These patients had already undergone multiple lines of unsuccessful treatment, placing them in a very difficult clinical situation with few therapeutic alternatives. In this context, the new academic HSP-CAR30 therapy developed at IR Sant Pau has achieved high rates of long-lasting responses, with patients remaining disease-free for more than three years. This confirms the potential of second-generation CAR-T therapies designed at the same center.

In the Phase I clinical trial, all patients treated responded to therapy. Moreover, half achieved complete remission, meaning the disease completely disappeared in imaging studies and follow-up clinical analyses. Another relevant finding is that these responses have been sustained over time in a large proportion of cases, demonstrating that the therapy is not only effective in the short term but also capable of inducing long-term disease control. Phase II of the trial, the only one of its kind in Europe, will conclude this October, marking a milestone in the history of CAR-T therapy.

Dr. Javier Briones, head of the Cellular Immunotherapy and Gene Therapy Group at IR Sant Pau and the Hematology Service at Sant Pau Hospital, who is responsible for developing these therapies, emphasized, “The high overall response rate is very uncommon in patients who have undergone multiple lines of treatment. Moreover, 50% achieved complete remission, with the disease disappearing in imaging studies and clinical analyses. This is crucial because it demonstrates that the persistence of CAR-T cells has a real and sustained effect on the disease, which is precisely what we seek.”

The CXCR4 Receptor: A Key Target Against Metastasis

Cancer research at IR Sant Pau is not limited to CAR-T therapies. Another major strategic focus of the institute is the study of the CXCR4 receptor, a protein that plays a fundamental role in tumor progression. Numerous studies have shown that its overexpression is associated with a greater ability of malignant cells to invade and spread, making it a true “Achilles’ heel” in multiple types of cancer.

The Oncogenesis and Antitumor Drugs Group, led by Dr. Ramon Mangues, has been researching CXCR4 for more than fifteen years. It has developed a unique nanomedicine platform capable of selectively directing therapeutic agents against tumor cells that express high levels of this receptor. These protein–drug nanoconjugates release their cytotoxic payload only in such cells, reducing adverse effects on healthy tissues.

In preclinical models, these nanoconjugates have shown high efficacy in both solid and hematologic tumors. In particular, a CXCR4-targeted nanotoxin was able to slow colorectal cancer growth and activate the patient’s immune response, opening possibilities for combinations with immunotherapy. In addition, the group has contributed to an international review on innovative therapies targeting CXCR4, positioning Sant Pau as an emerging reference in anti-metastatic treatments.

The strength of this research line has allowed the technology developed at Sant Pau to be transferred to the business sector through Nanoligent, a joint spin-off of the UAB and IR Sant Pau itself. The company, co-founded by Dr. Mangues, is currently focusing its efforts on the clinical development of CXCR4-targeted nanoconjugates, with the goal of making them available to patients in the coming years. This step reflects the institute’s commitment to translational innovation and collaboration with the biotechnology sector to accelerate the arrival of new treatments to the healthcare system.

Dr. Ramon Mangues stressed, “Metastasis remains the leading cause of cancer-related death, and CXCR4 is key in this process. Targeting it precisely allows us to selectively destroy the most aggressive cells while reducing toxicity. Our experience places us in a unique position to move forward toward anti-metastatic therapies with clinical potential in the coming years.”

Cancer Research Expands at Sant Pau

IR Sant Pau’s commitment to cancer research is also reflected in the creation of new specialized groups. One of them is the TRAIL Group (Thoracic Surgery Research and Innovation in Lung Cancer), led by Dr. Juan Carlos Trujillo-Reyes, which focuses its work on lung cancer, the leading cause of cancer death worldwide. Its research lines range from early diagnosis through screening programs to improving surgical techniques, with a special emphasis on robotic surgery, as well as integrating molecular and clinical biomarkers into clinical practice.

Another newly created group is the Gynecological and Breast Pathologies Group, coordinated by Dr. Silvia Cabrera Daz. This group focuses its research on gynecological neoplasms—endometrium, ovary, uterus, vulva, vagina, and breast—as well as benign pathologies with major impact on women’s quality of life, such as endometriosis, fibroids, and chronic pelvic pain. With a multidisciplinary approach, the group combines clinical care, teaching, and research, with the goal of generating cutting-edge knowledge and improving women’s healthcare in a highly complex hospital setting.

An international group of experts, including Dr. Saül Martínez-Horta, researcher at the Sant Pau Research Institute (IR Sant Pau) and neuropsychologist at the Movement Disorders Unit of Hospital Sant Pau, has published in the journal Movement Disorders a scientific review that thoroughly analyzes the most widely used neuropsychological tools to assess attention, working memory, and executive functions in Parkinson’s disease. The work, promoted by the International Parkinson and Movement Disorder Society (MDS), provides clear recommendations on which instruments should be used for a more accurate evaluation of the cognitive status of these patients, both in clinical practice and in research.

The evaluation of these cognitive functions is key because their deterioration is one of the most common non-motor complications in Parkinson’s disease. It can appear in very early stages, even before motor symptoms, and is associated with a progressive loss of autonomy and quality of life. However, the great variety of existing tests, differences in their psychometric quality, and the lack of unified criteria have so far hindered consistent assessment. According to Dr. Martínez-Horta, “It is not enough to use any test available; we need instruments with a solid scientific basis, adapted to the clinical reality of the Parkinson’s patient, and that allow us to detect subtle but significant changes.”

Eight Tests With the Highest Guarantees

The review assessed a total of 30 instruments and concluded that 8 of them offer the best guarantees of reliability, validity, and clinical applicability. Four focus mainly on attention and working memory: three subtests of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV)—Digit Span, which measures immediate memory and the ability to manipulate information; Coding, which evaluates processing speed and visuomotor coordination; and Symbol Search, which examines speed in visual discrimination and concentration—as well as the Trail Making Test, which analyzes processing speed, mental flexibility, and visual search. The WAIS-IV is one of the most widely used scales internationally to measure cognitive abilities, and its subtests provide results that can be compared with large normative datasets.

The other four recommended tests are oriented toward executive functions: Similarities, another WAIS-IV subtest that explores abstract verbal reasoning; the Wisconsin Card Sorting Test, considered the benchmark for evaluating cognitive flexibility and the ability to adapt to new rules; the Verbal Fluency Tests, which measure the ability to generate words according to phonemic or semantic criteria; and the Stroop Color-Word Test, in its abbreviated Victoria version, which evaluates the inhibition of automatic responses and adaptation to changing conditions. As Dr. Martínez-Horta points out, “These tools have not only proven to be reliable and valid, but they are also sensitive to changes that occur during the disease and to the effects of certain treatments.”

From Theory to Clinical Practice

For the authors, having this classification has an immediate impact on clinical practice, as it provides professionals with a clear guide to making informed decisions. Dr. Martínez-Horta emphasizes that “In the clinic, choosing the right test can make the difference between detecting an early cognitive change or overlooking it.” This is especially relevant in Parkinson’s disease, where cognitive changes may be subtle in the early stages and go unnoticed if tools with sufficient sensitivity are not used.

The review also highlights that the selection of the test should be adapted not only to the purpose of the evaluation—early detection, long-term monitoring, or assessing the effect of therapies—but also to the characteristics and limitations of the patient. Factors such as educational level, emotional state, fatigue, or motor fluctuations can influence performance and, therefore, the interpretation of results. “If a patient presents motor impairment that makes writing or manual speed difficult, a test requiring these skills could show low performance not because of a real cognitive deficit, but because of interference from motor symptoms,” the researcher explains. In such cases, the recommendation is to prioritize verbally administered or adapted tools that minimize the impact of these limitations.

The paper stresses that using standardized, evidence-based tests improves diagnostic accuracy and promotes homogeneity in research, making it easier to compare results across different centers and studies. This, in turn, helps advance knowledge of the disease and develop more effective interventions to preserve cognitive function.

An International Reference Framework

The review establishes which tests are the benchmarks and identifies those that, despite their common use, have limitations and require further research to confirm their utility. The analysis indicates that some widely used instruments lack normative studies specific to the Parkinson’s population or present reliability issues when applied in real-world clinical contexts. In such cases, the expert group recommends cautious use, always combined with complementary measures.

For Dr. Martínez-Horta, this work represents “an important step toward standardizing cognitive evaluation in Parkinson’s disease on a global scale.” The researcher stresses that “We want this guide to serve as a tool to unify criteria and improve the quality of cognitive evaluations in Parkinson’s disease worldwide.” Having an international reference framework allows data obtained in different countries and centers to be comparable, which is essential for establishing progression patterns, identifying risk factors, and evaluating the impact of new treatments.

In addition, homogeneity in the choice of tools will make it possible to integrate large international databases, fostering collaborative studies with larger and more representative samples. “Homogeneity in evaluation is key to advancing research, comparing data between centers, and ultimately offering better care to patients,” he concludes. The ultimate goal, as the author group highlights, is for this consensus to translate into more precise evaluations, earlier diagnoses, and more effective intervention strategies.

Reference Article:

Biundo R, Bezdicek O, Cammisuli DM, Cholerton B, Dalrymple-Alford JC, Edelstyn N, Fiorenzato E, Holker E, Martinez-Horta S, Martini A, Santangelo G, Segura B, Siri C, Tröster A, Mestre TA, Ferro ÁS, Hyczy de Siqueira Tosin M, Skorvanek M, Weintraub D, Geurtsen GJ, and the members of the MDS Clinical Outcome Assessment Scientific Evaluation Committee. Attention/working memory and executive function in Parkinson’s disease: Review, critique, and recommendations. Mov Disord 2025. https://doi.org/10.1002/mds.30293

A review article published in Nature Reviews Neurology, whose first author is Dr. Marta Caballero from the team of Dr. Luis Querol, member of the Neuromuscular Diseases Group at the Sant Pau Research Institute (IR Sant Pau), analyzes recent advances in the diagnosis and treatment of primary autoimmune neuropathies—a group of rare and debilitating disorders of the peripheral nervous system that includes Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

For more than three decades, the therapeutic approach to these disorders has relied on nonspecific strategies such as intravenous immunoglobulin, corticosteroids, or plasma exchange. Although these have improved the prognosis for many patients, their effectiveness is limited, and not everyone responds in the same way. Moreover, these therapies do not target the specific mechanisms that trigger the disease.

A New Direction

The review article explains how, lately, research has enabled a qualitative leap in this field. One of the most significant advances is the identification of autoantibodies directed against essential proteins at the nodes of Ranvier—structures critical for the transmission of nerve impulses. This finding, in which the Neuromuscular Diseases Unit at Sant Pau Hospital has played a leading role, led to the recognition of a new diagnostic category: autoimmune nodopathies. These are neuropathies in which the immune system specifically attacks these regions of the nerve fiber, disrupting communication between neurons and causing weakness and loss of sensation.

This new concept helps explain the clinical heterogeneity of some patients and opens the door to more targeted treatments. At the same time, the diagnostic criteria for GBS and CIDP have been redefined, enabling more accurate detection of disease, reducing misclassification, and better guiding therapeutic decisions.

The article coordinated by Dr. Querol also reviews targeted therapies that are beginning to reach clinical practice. A notable example is efgartigimod, recently approved in Europe and the United States as the first specific treatment for CIDP. This drug lowers the levels of pathogenic antibodies in the blood and represents a paradigm shift after more than 30 years without therapeutic innovations of this magnitude. In addition, clinical trials are underway with complement inhibitors, which have shown promising results not only in CIDP but also in GBS and multifocal motor neuropathy.

Another key aspect is biomarkers, which provide objective information about disease activity and progression. Among the most promising are serum neurofilament light chain, which reflects axonal damage, as well as specific autoantibodies and proteins unique to peripheral nerves, such as peripherin or periaxin. Validating these biomarkers will not only allow earlier diagnosis but also help predict treatment response and personalize patient follow-up.

A Transformation in Patient Care

“The field of autoimmune neuropathies is undergoing a true transformation,” explains Dr. Marta Caballero. “We are moving from general therapies to strategies that target the exact mechanisms causing the disease. This means we will be able to be much more precise, reduce treatment toxicity, and improve patients’ quality of life.”

Dr. Querol, for his part, emphasizes the importance of the new biomarkers. “Thanks to these tools, we will not only be able to diagnose more quickly and reliably, but also to monitor disease progression and treatment response in an objective way. This is an essential step toward advancing personalized medicine in this field.”

The advances summarized in this review place primary autoimmune neuropathies—until now considered orphan diseases in terms of innovation—at the center of a paradigm shift. More profound understanding of their mechanisms, the availability of more rigorous diagnostic criteria, the arrival of new targeted therapies. The development of reliable biomarkers will allow patients to receive care that is more effective, safer, and tailored to their individual needs.

Reference Article:

Caballero-Ávila M, Pascual-Goñi E, Lleixà C, Martín-Aguilar L, Collet-Vidiella R, Querol L. The changing landscape of primary autoimmune neuropathies. Nat Rev Neurol 2025. https://doi.org/10.1038/s41582-025-01133-3

During September and October, My Alma, a brand specialized in intimate and menstrual wellness products, is launching a solidarity campaign to support ovarian cancer research at the Sant Pau Research Institute.

For every product sold through its online store, My Alma will donate a solidarity round-up, which will become a direct contribution to fund a pioneering project at our center.

A company committed to women’s health

My Alma was created with the mission of placing women’s health at the center, offering more sustainable, healthy, and body- and environmentally-friendly products. Inspired by her own personal experience, its founder also wanted the brand to become a driver of social change, raising awareness and providing resources for medical research that directly affects women.

Supporting ovarian cancer research

The funds raised will go to an innovative project at the Sant Pau Research Institute that studies how signals from the nervous system can influence the growth and spread of tumors. The goal is to find new strategies to tackle ovarian cancer that is resistant to current treatments and to offer new hope to patients.

Raising awareness to break taboos

As part of this collaboration, My Alma and Sant Pau will also publish a series of educational video capsules, created by Sant Pau professionals, on topics related to menstruation. The aim is to provide rigorous information, promote women’s health, and help break down taboos that are still present in society.

A collaboration with impact

Through this initiative, My Alma and the Sant Pau Research Institute are joining forces to advance research and improve the lives of women living with this disease, while also promoting awareness and health education.

The Sant Pau Research Institute (IR Sant Pau) has approved the creation of the new research group TRAIL (Thoracic Surgery Research and Innovation in Lung Cancer), dedicated to advancing research and innovation in the field of thoracic surgery and lung cancer. The group will be led by Dr. Juan Carlos Trujillo-Reyes, head of the Joint Thoracic Surgery Service of Sant Pau and del Mar hospitals. The founding members of the new group, in addition to Dr. Trujillo, are Dr. Elisabeth Martínez, a specialist in minimally invasive techniques and in improving patients’ quality of life, and Dr. Josep Belda Sanchis, a thoracic surgeon with more than thirty years of experience in complex lung surgery and oncological pathology.

According to Dr. Trujillo, “Lung cancer remains the leading cause of cancer mortality worldwide and in Spain. That is why it is essential to commit to research and innovation in early diagnosis and advanced surgical techniques that allow us to improve outcomes and patient survival.”

TRAIL was established with the goal of consolidating high-quality research with a real impact on clinical practice. It is a pioneering and distinctive initiative within the national landscape, standing out for its innovative character and the uniqueness of its proposal in the current research context. Its main lines of research include early diagnosis of lung cancer through screening programs and advanced imaging techniques; optimal surgical selection after induction treatments; improvement of surgical techniques and perioperative outcomes, with a special focus on robotic surgery and prehabilitation programs; and translational research on biomarkers to integrate molecular and clinical data into therapeutic decision-making.

“Sant Pau offers us a privileged environment to develop high-level research, thanks to multidisciplinary collaboration and a direct connection with clinical practice. This synergy is key to generating knowledge that has an immediate impact on patients,” says Dr. Trujillo.

Dr. Juan Carlos Trujillo earned his degree in medicine and surgery from the Autonomous University of Barcelona (2009) and his PhD in medicine from the same university (2022). A specialist in thoracic surgery, he has worked at Sant Pau since 2015 and has been one of the main drivers of minimally invasive surgery at the center. He combines his clinical activity with teaching as an associate professor at the Autonomous University of Barcelona (UAB) and with an outstanding research career, with more than 60 publications in high-impact journals.

He has played a key role in the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR), where he coordinated the Thoracic Oncology Area and the CASSANDRA project, the first nationwide pilot study on lung cancer screening. Furthermore, he currently coordinates SEPAR’s research and development projects in thoracic oncology and is co-director of the national thymic tumor database. In 2024, he received SEPAR’s Young Investigator of the Year Award.

According to Dr. Trujillo, “The creation of the TRAIL group allows us to structure and strengthen all the work we are already doing in research and innovation in thoracic surgery and lung cancer. Our goal is to generate useful knowledge that translates into better patient care and reduced mortality from this disease.”

With its creation, TRAIL aims to consolidate Sant Pau as a reference center for research and innovation in thoracic surgery and lung cancer, promoting multidisciplinary synergies and training new generations of professionals in the biomedical field.